[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100414753":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":27,"responsibleParty":62,"collaborators":19,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":19,"enrollmentInfo":74,"targetDuration":19,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":19,"overallStatus":48,"whyStopped":19,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Centre Antoine Lacassagne","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Per-Operative Radiotherapy technique by Papillon +TM","EXPERIMENTAL","Per-Operative Radiotherapy (1x20Gy) technique by Papillon +TM",[13],"Radiation: Per-Operative Radiotherapy technique by Papillon +TM",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"RADIATION","20Gy Per-Operative Radiotherapy technique by Papillon +TM, on localized breast cancer",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"Frédérique JACQUINOT","CONTACT","04 92 03 10 24","+33","drci-promotion@nice.unicancer.fr",[28,47],{"facility":29,"status":30,"city":31,"state":19,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Pôle Santé République","NOT_YET_RECRUITING","Clermont-Ferrand","63000","France","FR",{"type":36,"coordinates":37},"Point",[38,39],3.08682,45.77969,{"lat":39,"lon":38},[42,44],{"name":43,"role":23,"phone":19,"phoneExt":19,"email":19},"Annie ITIE",{"name":45,"role":46,"phone":19,"phoneExt":19,"email":19},"Vivien FUNG, Dr","PRINCIPAL_INVESTIGATOR",{"facility":5,"status":48,"city":49,"state":19,"zip":50,"country":33,"countryCode":34,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"RECRUITING","Nice","06189",{"type":36,"coordinates":52},[53,54],7.26608,43.70313,{"lat":54,"lon":53},[57,60],{"name":58,"role":23,"phone":59,"phoneExt":25,"email":19},"Damien CHAUVIERE","0492031365",{"name":61,"role":46,"phone":19,"phoneExt":19,"email":19},"Marie-Eve FOUCHE-CHAND, Dr",{"type":63,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100414753","phase-2-per-operative-radiotherapy-by-papillon-tm-in-localized-breast-cancer-100414753",false,"NCT04680715","Per-Operative Radiotherapy by Papillon +TM in Localized Breast Cancer","Per-Operative Radiotherapy (RPO) by Papillon +TM in Localized Breast Cancer : Faisability and Toxicity Study","RPOS+2","Inclusion Criteria:\n\n* Patient with invasive ductal adenocarcinoma \\\u003C=2cm, evaluate on all radiological exams;\n* Women aged 65 years or older (patients 65 years of age in the year may be included);\n* Grade 1 or 2 unifocal adenocarcinoma, all index KI67, positive HR, negative HER2 status;\n* T0 or T1, N0 radio-clinic;\n* Operable patient with breast volume compatible with conservative surgery;\n* Patient with prior malignancy or other concurrent malignancies are eligible, including bilateral breast cancer\n* Patients who have been made aware of the information sheet and have given their written signed informed consent;\n* Patients benefitting from social health insurance coverage\n\nExclusion Criteria:\n\n* Age less than 65 years (except if 65 years obtained during the year)\n* Patient with an exclusive in situ carcinoma\n* Patient with lymphatic invasion \u002F peri-nerve involvement \u002F vascular emboli\n* Patient with a lobular adenocarcinoma\n* Patient with metastatic disease\n* Multifocal tumor\n* Patient with grade 3 or N+ disease\n* N1 proved by ultrasound guided\n* patient unable to express her consent\n* Patient deprived placed under the authority of a tutor\n* Female patients who are pregnant or breastfeeding\n* Vulnerable patient: as defined in article L1121-5 à -8","FEMALE","65 Years",{"count":75,"type":76},40,"ESTIMATED","INTERVENTIONAL",[79],"PHASE2","Phase II study; open recruitment, multicentrique. The aim of this clinical research is to evaluate faisability and toxicity of the per-operative radiotherapy using PAPILLON + TM device for localized breast cancers patients over 65 years.",[82],"Localized Breast Cancer","2026-01-28",{"date":85,"type":86},"2026-01-29","ACTUAL",{"date":88,"type":86},"2021-07-16",{"date":90,"type":76},"2028-06",{"name":5,"class":6},2]